Niagen Bioscience, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.8M | $31.5M | $33.8M | $34.0M | $31.1M | $30.5M | $29.1M | $25.6M |
| Cost of Revenue | $10.5M | $11.5M | $12.1M | $12.1M | $10.9M | $11.2M | $10.9M | $9.3M |
| Gross Profit | $19.3M | $20.0M | $21.7M | $21.9M | $20.2M | $19.3M | $18.2M | $16.2M |
| Gross Margin | 64.8% | 63.5% | 64.1% | 64.5% | 65.0% | 63.4% | 62.5% | 63.5% |
| Operating Expenses | ||||||||
| Research & Development | $1.5M | $1.5M | $1.7M | $1.8M | $1.6M | $1.3M | $1.3M | $1.3M |
| SG&A Expense | $7.0M | $7.2M | $7.5M | $7.1M | $7.3M | $5.2M | $1.1M | $6.3M |
| Operating Income | $700.0K | $1.6M | $4.1M | $4.2M | $3.2M | $4.8M | $7.1M | $1.6M |
| Operating Margin | 2.4% | 5.0% | 12.1% | 12.5% | 10.2% | 15.7% | 24.4% | 6.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $1.1M | $6.7M | $4.4M | $4.8M | $3.7M | $5.2M | $7.5M | $1.9M |
| Income Tax Expense | $106.0K | $417.0K | $292.0K | $222.0K | $128.0K | $168.0K | $305.0K | $0 |
| Net Income | $963.0K | $6.3M | $4.1M | $4.6M | $3.6M | $5.1M | $7.2M | $1.9M |
| Net Margin | 3.2% | 20.1% | 12.2% | 13.5% | 11.6% | 16.6% | 24.6% | 7.3% |
| EPS (Basic) | $0.01 | $0.08 | $0.04 | $0.06 | $0.05 | $0.07 | $0.10 | $0.02 |
| EPS (Diluted) | $0.01 | $0.07 | $0.05 | $0.05 | $0.04 | $0.06 | $0.10 | $0.02 |
| Shares Outstanding (Basic) | 79.3M | 79.9M | 79.2M | 79.8M | 79.2M | 77.8M | 75.9M | 76.0M |
| Shares Outstanding (Diluted) | 82.5M | 84.6M | 85.4M | 86.6M | 86.2M | 83.2M | 78.1M | 77.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |